142 related articles for article (PubMed ID: 2360919)
1. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
Regnström J; Walldius G; Carlson LA; Nilsson J
Atherosclerosis; 1990 May; 82(1-2):43-51. PubMed ID: 2360919
[TBL] [Abstract][Full Text] [Related]
2. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
Regnström J; Walldius G; Nilsson S; Elinder LS; Johansson J; Mölgaard J; Holme I; Olsson AG; Nilsson J
Atherosclerosis; 1996 Sep; 125(2):217-29. PubMed ID: 8842353
[TBL] [Abstract][Full Text] [Related]
3. The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).
Walldius G; Regnström J; Nilsson J; Johansson J; Schäfer-Elinder L; Moelgaard J; Hådell K; Olsson AG; Carlson LA
Am J Cardiol; 1993 Feb; 71(6):15B-19B. PubMed ID: 8434556
[TBL] [Abstract][Full Text] [Related]
4. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
Reaven PD; Parthasarathy S; Beltz WF; Witztum JL
Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191
[TBL] [Abstract][Full Text] [Related]
5. Probucol inhibits oxidative modification of low density lipoprotein.
Parthasarathy S; Young SG; Witztum JL; Pittman RC; Steinberg D
J Clin Invest; 1986 Feb; 77(2):641-4. PubMed ID: 3944273
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia.
Masana L; Bargalló MT; Plana N; LaVille A; Casals I; Solà R
Am J Cardiol; 1991 Oct; 68(9):863-7. PubMed ID: 1927944
[TBL] [Abstract][Full Text] [Related]
7. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
[TBL] [Abstract][Full Text] [Related]
8. Concentration-dependent antioxidant activity of probucol in low density lipoproteins in vitro: probucol degradation precedes lipoprotein oxidation.
Barnhart RL; Busch SJ; Jackson RL
J Lipid Res; 1989 Nov; 30(11):1703-10. PubMed ID: 2614272
[TBL] [Abstract][Full Text] [Related]
9. The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881.
Feldman DL; Mogelesky TC; Sharif R; Sawyer WK; Jeune M; Hu CW; Leonards KS; Prescott MF
Atherosclerosis; 1999 Jun; 144(2):343-55. PubMed ID: 10407495
[TBL] [Abstract][Full Text] [Related]
10. Probucol: effects on the metabolism of low density and high density lipoproteins in moderate hypercholesterolaemia.
Magill P; Whiting C; Hammett F; Glick I; Miller NE; Lewis B
Artery; 1982; 10(2):88-94. PubMed ID: 7092581
[TBL] [Abstract][Full Text] [Related]
11. Studies on the mechanism of action of probucol.
Steinberg D
Am J Cardiol; 1986 Jun; 57(16):16H-21H. PubMed ID: 3728306
[TBL] [Abstract][Full Text] [Related]
12. Influence of probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients.
Lussier-Cacan S; Dubreuil-Quidoz S; Roederer G; Leboeuf N; Boulet L; de Langavant GC; Davignon J; Naruszewicz M
Arterioscler Thromb; 1993 Dec; 13(12):1790-7. PubMed ID: 8241099
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of low density lipoprotein oxidation by thyronines and probucol.
Hanna AN; Feller DR; Witiak DT; Newman HA
Biochem Pharmacol; 1993 Feb; 45(3):753-62. PubMed ID: 8442772
[TBL] [Abstract][Full Text] [Related]
14. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.
Yamamoto A; Hara H; Takaichi S; Wakasugi J; Tomikawa M
Am J Cardiol; 1988 Jul; 62(3):31B-36B. PubMed ID: 3394651
[TBL] [Abstract][Full Text] [Related]
15. Structural changes in oxidised low-density lipoproteins and of the effect of the anti-atherosclerotic drug probucol observed by synchrotron X-ray and neutron solution scattering.
Bellamy MF; Nealis AS; Aitken JW; Bruckdorfer KR; Perkins SJ
Eur J Biochem; 1989 Aug; 183(2):321-9. PubMed ID: 2759086
[TBL] [Abstract][Full Text] [Related]
16. Low-dose colestipol plus probucol for hypercholesterolemia.
Dujovne CA; Chernoff SB; Krehbiel P; Jackson B; DeCoursey S; Taylor H
Am J Cardiol; 1984 Jun; 53(11):1514-8. PubMed ID: 6375337
[TBL] [Abstract][Full Text] [Related]
17. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.
Carew TE; Schwenke DC; Steinberg D
Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7725-9. PubMed ID: 3478721
[TBL] [Abstract][Full Text] [Related]
18. Differing effects of probucol and vitamin E on the oxidation of lipoproteins, ceroid accumulation and protein uptake by macrophages.
Hunt JV; Bottoms MA; Taylor SE; Lyell V; Mitchinson MJ
Free Radic Res; 1994 Mar; 20(3):189-201. PubMed ID: 8019642
[TBL] [Abstract][Full Text] [Related]
19. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
Tomikawa M; Nakayasu T; Tawara K; Abiko Y
Atherosclerosis; 1981 Oct; 40(2):101-13. PubMed ID: 6946776
[TBL] [Abstract][Full Text] [Related]
20. Probucol (Lorelco) in treatment of hyperlipemia.
Murphy BF
JAMA; 1977 Dec; 238(23):2537-8. PubMed ID: 199758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
